Technology
Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform
Published
2 years agoon
By
Supporting Rakuten Medical’s efforts to accelerate its global Phase 3 study with the goal of achieving approval of ASP-1929 in US as soon as possibleAlso supporting development of additional pipeline using the Alluminox™ platform, including ASP-1929 photoimmunotherapy in combination with anti-PD-1, development of new drugs and devices, and further leveraging learnings from real-world experiences in ASP-1929 photoimmunotherapyNew investments by Hikma, a global pharmaceutical company, and Mizuho Bank and Dai-ichi Life, leading financial institutions in Japan, as well as additional investments by SBI Group, Rakuten Group and its Chairman and CEO, Mickey MikitaniMazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA region joins the board of directors to fuel the next chapter of growth
SAN DIEGO, March 6, 2024 /PRNewswire/ — Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest.
Rakuten Medical intends to further develop its proprietary Alluminox™ platform and contribute to the future of patients and healthcare around the world by allocating the funds raised for the following business priorities:
Continuing efforts to accelerate its global Phase 3 clinical trial (ASP-1929-301 study, ClinicalTrials.gov Identifier: NCT03769506) of Alluminox treatment (photoimmunotherapy) using ASP-1929, with the goal of achieving approval of ASP-1929 in the United States and several other countries and regions as soon as possibleSupporting ongoing clinical trials and initiating new studies for Alluminox treatment using its three key assets (ASP-1929, RM-1995, and RM-0256), including combination therapy with anti-PD-1, which has shown promising early data that Rakuten Medical believes warrant additional clinical studiesIn-house discovery of new drug conjugates under its drug discovery program, Alluminox Palette™Development of new medical devices to improve treatment in the clinic and trialsLeveraging learnings and experience from Alluminox treatment in the commercial setting in Japan in an effort to improve patient outcomes and for further understanding and development of this treatment technology
Mickey Mikitani, Co-CEO of Rakuten Medical, commented, “We are very proud to have raised $119 million in Series E financing despite the challenging market environment for biotechnology companies in 2023, when we started this financing round. I would like to thank our many investors for having valued our achievements and great potential. The Alluminox™ platform will continue to evolve, and together with our trusted business partners and the healthcare professionals who believe in our technology, we will expand this innovative therapy both geographically and clinically, and pave the way for a brighter future.”
One of the major investors in this Series E Financing is Hikma Pharmaceuticals PLC (“Hikma”), a global pharmaceutical company headquartered in the UK, with a local presence across the MENA region, North America and Europe. Other major investors include existing investors such as Rakuten Group, Inc., a global internet services company and its Chairman and CEO, Mickey Mikitani, and SBI Group, a leading venture capital firm in Japan, as well as new investors Mizuho Bank, Ltd. and the Dai-ichi Life Insurance Company, Limited, leading Japanese financial institutions.
Rakuten Medical also welcomed Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA region, to its Board of Directors. Darwazah is an experienced executive with more than 38 years of pharmaceutical industry experience gained through serving in various positions within the Hikma Group. With his strong operational direction and experience in driving strategic business decisions that grow healthcare businesses in the MENA region and globally, Darwazah will add value as a solid guide for Rakuten Medical as it moves to a new stage of uncovering more potential as a global biotechnology company.
In making this investment and appointment to the Board of Directors, Darwazah commented, “I am honoured to join Rakuten Medical’s board. Through this appointment, I am looking forward to driving synergies and facilitating a closer working relationship with an important partner that shares Hikma’s vision of shaping a healthier world.”
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing and tumor necrosis. Alluminox therapies have not yet been approved outside of Japan. Rakuten Medical is committed to its mission to conquer cancer by delivering its innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com.
About Alluminox™ platform
The Alluminox™ platform is an investigational technology platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is developing the Alluminox platform as a technology consisting of a drug, device, and other related components. The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding. The device component consists of a light source that locally illuminates the targeted cells with light to transiently activate the drug. Pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted cancer cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Outside of Japan, Alluminox therapies have not yet been approved by any regulatory authority.
Forward Looking Statements
This press release contains forward looking statements. These statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions that may cause Rakuten Medical’s business plans and results to differ from the anticipated results and expectations expressed in these statements. These “forward looking statements” contain information about the plans, status and development of our research, clinical trials and products, including the Alluminox™ platform, combination therapies, product and developmental candidates and related medical devices, as well as our commercial activities, other regulatory and marketing authorization efforts; the potential benefits, efficacy, and safety of our product candidates or other therapies created using the Alluminox platform, and the status, plans and timing of regulatory filings and approvals therefor; plans to advance other pipeline product candidates or discovery efforts; the Company’s ability to leverage learnings from experiences in ASP-1929 photoimmunotherapy; and the intended use of proceeds from the financing. The approval and commercial success of any of our products or product candidates may not be achieved. Such statements may include words such as “expect,” “believe,” “hope,” “estimate,” “looks as though,” “anticipate,” “intend,” “may,” “suggest,” “plan,” “target,” “contemplate,” “predict,” “potential,” “continue,” “strategy,” “will,” and “do”, and are based on our current beliefs. In addition, this press release uses terms such as “important,” “notable,” and “abnormal” to express opinions about clinical trial data. Ongoing clinical trial studies include various risks and uncertainties, in particular, problems that arise during the manufacturing stage of our therapies, the occurrence of adverse safety events and situations and failure to demonstrate therapeutic benefits, and other various risks and uncertainties, both reasonable and unreasonable. For this reason, actual results, including regulatory approvals and uncertainties in the commercialization process of our therapies, may differ from published information. Except to the extent required by applicable law, we undertake no obligation to publicly update this or any other forward-looking statement, whether because of new information, future developments or events, changes in assumptions, changes in the factors affecting forward-looking statements. If one or more forward-looking statement(s) is updated, no inference should be drawn that additional updates will be made to those or other forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/rakuten-medical-closes-119-million-series-e-financing-to-further-develop-its-alluminox-platform-302081867.html
SOURCE Rakuten Medical, Inc.
You may like
Technology
Wearable Technology Market Expected to Reach $183.2 Billion by 2031, Growing at a CAGR of 12.75% — Allied Market Research
Published
15 minutes agoon
April 21, 2026By
Surge in AI & IoT-enabled smart wearables, rising healthcare monitoring demand, and expanding enterprise deployments are reshaping the global wearable technology market.
WILMINGTON, Del., April 21, 2026 /PRNewswire/ — Allied Market Research has published a comprehensive new report titled, “Wearable Technology Market by Device, Product Type, and Application: Global Opportunity Analysis and Industry Forecast, 2024–2033.” According to the report, the global wearable technology market size was valued at USD 54.8 billion in 2020 and is projected to reach USD 183.2 billion by 2031, registering a CAGR of 12.75% from 2022 to 2031. Rising global rates of chronic disease, post-pandemic behavioral shifts toward preventive health, and the accelerating integration of artificial intelligence and IoT connectivity into wearable devices are the primary forces fueling robust wearable technology market growth across consumer, clinical, and enterprise segments.
Download Sample Pages of Research Overview:
https://www.alliedmarketresearch.com/request-sample/355
Key Market Snapshot
Report Title
Wearable Technology Market — Global Opportunity Analysis & Industry Forecast, 2024–2033
Market Size (2020)
USD 54.8 Billion
Market Forecast (2031)
USD 183.2 Billion
CAGR (2022–2031)
12.75 %
Leading Segment by Product
Smartwatches & Fitness Bands
Leading Application
Healthcare & Medical Monitoring
Leading End User
Consumer Electronics Segment
Dominant Region
North America
Fastest Growing Region
Asia-Pacific
Top Growth Driver
AI & IoT-Enabled Wearable Devices
Report Coverage
2017–2033 | Multi-segmented, Multi-regional
Buy This Research Report (196 Pages PDF with Insights, Charts, Tables, and Figures): https://www.alliedmarketresearch.com/checkout-final/7dbb6a5d788644207905e99b6b05cfe6
Key Market Insights
Market Size: The global wearable technology market was valued at USD 54.8 billion in 2020 and is projected to reach USD 183.2 billion by 2031 growing at a CAGR of12.75% making it one of the fastest-growing consumer electronics and digital health segments worldwide.The Smartwatches and fitness bands, who are not only growing the presence in the field of heart rate tracking or sleep tracking but also new product advances such contactless payments along with smartphone features basically serving needs for both a proliferation of wellness consumers and burgeoning population of more clinically oriented users.The Highest Growing Application Vertical: Healthcare and medical monitoring is the fastest-growing segment of application vertical, due to increasing clinical validation for ECG monitoring, blood glucose estimation, SpO2 tracking & fall detection in wearable devices — allowing continuous remote patient management.Hearables as a New Subsector: A growing sector of wearables, hearables — smart earbuds and AI-driven hearing aids are one of the most dynamic wearable categories now, propelled further by relaxation of US regulations on over-the-counter (OTC) hearing aids.Regional Leaders: North America led the market for global wearable technology in 2020 due to high consumer technology adoption, advanced healthcare infrastructure and a strong ecosystem for employer-subsidized wellness programs.Largest Growth Frontier: Equipped with increasing smartphone penetration, expanding urban middle class incomes, and large young rural populations across India, China, South Korea & Southeast Asia; AsiaPacific is undoubtedly the fastest growing region.Artificial intelligence (AI) as an Enabler: The addition of AI built directly into wearables — delivering personalized fitness coaching, real-time alerts to changes in health conditions, anomaly detection and predictive analytics — will finally be transforming the nature of smart watches from mere data collectors to actual intelligent health companions.
Technology Drivers
Introduction There are several converging technologies that will redefine usage wearables. On-device AI and machine learning provide personal fitness recommendations, real-time health alerts, and behavioral coaching to individual users which will drive stickiness on the platform The widespread emergence of 5G infrastructure worldwide is enabling low-latency biosignal streaming to cloud health platforms, paving the way for new use cases in remote patient monitoring and augmented reality wearables along with industrial safety applications.
Flexible batteries, which can keep power-hungry chip designs thinner and allow energy harvesting from body heat and motion, combined with increasingly compact chip design are helping create tinier devices that provide better fulfillment of consumer expectations surrounding comfort and aesthetics. With the birth of smart ring category — small, low-power and unobtrusive devices —shows that appetite is growing for wearable form factors beyond the wrist.
Enquiry Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/355
Market Segmentation
Based on Product Type: Smartwatches: & amp; Fitness bands, hearables, medical wearables smart glasses and smart clothing.
By Application: Sports and fitness is still the largest segment by volume, while healthcare and medical monitoring is fastest-growing as biosensors receive clinical validation (for arrhythmia detection), continuous glucose monitoring and chronic disease management.
Global Shipments of Device by End User: Individual consumers are the leader in global shipments of devices. But healthcare providers and enterprise clients are scaling too quickly as wearables move past consumer toys to actual clinical and operational tools with credible ROI. Through comprehensive employee wellness programs, enterprises throughout North America and Europe are integrating wearables into their health initiatives that form another valuable institutional procurement channel, next to where most consumer wearables are sold today retail.
Regional Insights
North America will occupy the largest revenue share as a growing middle class translates to overall health, with high levels of consumer technology adoption and a healthcare system that has embraced remote monitoring. Consumer health wearables are accelerating clinical validation with FDA clearances, and sustained demand is being created by employer subsidized wellness programs, over above direct retail
Technological advances coupled with significant smartphone penetration and an increasing middle-class income are propelling growth of the Asia-Pacific market, which is also home to some of the youngest populations in world (in India, China, South Korea and Southeast Asia). China has the combined characteristics of being the largest manufacturer in the world as well as a large domestic consumer market: many new brands compete fiercely on feature set and price. India is forecast to also experience one of the highest regional growth rates until 2033 from e-commerce expansion and rising urban health awareness.
Europe has a large presence, spinning off notably to the medical and sports performance space. Representing a different landscape of data governance that wearable health platforms face today, consumer privacy awareness is affecting the market and EU digital health regulations actively are shaping product development for manufacturers worldwide. Its the UK and Germany, France and the Nordic nations that are at the fore.
LAMEA (Latin America, Middle East, and Africa) is an emerging high-growth opportunity. In Saudi Arabia, the UAE and Qatar this institutional push for wearables is being supported by government-led incentives for Smart City and digital health initiatives. For Latin American adoption, Brazil leads and South Africa anchors the African wearables ecosystem.
Competitive Landscape
The market is defined by intense competition among technology giants, specialized medical device makers, and consumer electronics challengers:
Apple leads the smartwatch segment with its Apple Watch ecosystem, integrating consumer wellness with clinical-grade health monitoring.Samsung competes through its Galaxy Watch and Galaxy Buds portfolio, backed by the Samsung Health platform.Fitbit (Google) pioneered consumer fitness tracking and is now targeting clinical-grade health monitoring within Google’s broader digital health ecosystem.Garmin commands premium loyalty among athletes and outdoor professionals through precision GPS and biometric analytics.Huawei and Xiaomi dominate volume in Asia-Pacific — Huawei through advanced health sensing and Xiaomi through ultra-competitive pricing in emerging markets.Abbott, Dexcom, and Medtronic lead in medical wearables, particularly continuous glucose monitors and implantable cardiac devices.Meta and Snap are pursuing next-generation augmented reality smart glasses.
Recent Developments
There are a few major trends that will influence the direction of the market in the near term. Non-invasive Blood Glucose monitoring is one of the most awaited features in future smartwatches and for good reason too; it could unlock the world’s biggest diabetic care market. So far, large language model-based AI coaching assistants have been dispersed in wearable platforms and are producing tailored fitness, sleep and stress management advice. For Consumer Domestics: The FDA and CE Clearances for ECG, Atrial Fibrillation Detection, And Blood Oxygen Monitoring Have Notably Broadened the Clinical Legitimacy of Smartwatches from Consumers Ruggedized wearables for workplace safety and augmented reality-assisted operations will deliver a high-value B2B channel targeting enterprise and industrial deployments. With technology conglomerates, healthcare systems, and insurers all vying to consolidate platforms and intellectual property across connected health, strategic M&A and investment activity is accelerating.
Analyst Perspective
Structural Inflection Point for Wearable Tech Market With the largest-aged population globally, they require continuous non-invasive monitoring of heart, lung and brain health by detecting early symptoms. At the same time, healthcare systems pressed financially are transitioning to preventive care models — a switch in which clinically validated consumer wearables form a critical enabling play.
The synthesis of AI-enabled edge computing, 5G, next-generation biosensor arrays, and flexible electronics is creating a new class of devices that will serve not only as data collectors but also as smart health companions with capabilities for personalization, anomaly detection and integration across larger digital health systems.
For market stakeholders, the key success factors all remain constant; device accuracy and clinical validation (with effective engagement that engenders habitual use), platform ecosystem stickiness (entrenchment to create a barrier to competition), data privacy & regulatory compliance, and the demonstrated ability to deliver measurable health outcomes that warrant a premium price point for consumers or institutional uptake. Those companies getting all four of these dimensions right are best positioned to capture outsized value as the market scales through 2033
Explore AMR’s Extensive ongoing Coverage on Consumer and Goods Domain:
Smart Home Appliances Market: Global Opportunity Analysis and Industry Forecast, 2024 – 2034
https://www.alliedmarketresearch.com/smart-home-appliances-market
Digital Accessories Market: Global Opportunity Analysis and Industry Forecast, 2023-2032
https://www.alliedmarketresearch.com/digital-accessories-market
Home Entertainment Devices Market: Global Opportunity Analysis and Industry Forecast, 2022–2031
https://www.alliedmarketresearch.com/home-entertainment-devices-market
Hand Dryer Market: Global Opportunity Analysis and Industry Forecast, 2022–2031
https://www.alliedmarketresearch.com/hand-dryer-market
Electronic Cigarette Market: Global Opportunity Analysis and Industry Forecast, 2022–2031
https://www.alliedmarketresearch.com/electronic-cigarette-market
Air Humidifier Market: Global Opportunity Analysis and Industry Forecast, 2024 – 2033
https://www.alliedmarketresearch.com/air-humidifier-market
Smart Toys Market: Global Opportunity Analysis and Industry Forecast, 2023 – 2033
https://www.alliedmarketresearch.com/smart-toys-market
Dehumidifier Market: Global Opportunity Analysis and Industry Forecast, 2022 – 2032
https://www.alliedmarketresearch.com/dehumidifier-market
Action camera Market: Global Opportunity Analysis and Industry Forecast 2021–2027
https://www.alliedmarketresearch.com/action-camera-market
Residential Washing Machine Market: Global Opportunity Analysis and Industry Forecast, 2020-2031
https://www.alliedmarketresearch.com/residential-washing-machine-market
About Us
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Allied Market Research Blog: https://blog.alliedmarketresearch.com
Follow Us on | Facebook | LinkedIn | YouTube |
Logo: https://mma.prnewswire.com/media/636519/5918347/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/wearable-technology-market-expected-to-reach-183-2-billion-by-2031–growing-at-a-cagr-of-12-75—-allied-market-research-302748411.html
SOURCE Allied Market Research
Technology
AI Innovation Surges as Security Fundamentals Lag, Kroll Research Finds
Published
15 minutes agoon
April 21, 2026By
Key Takeaways
76% of organizations have experienced a security incident involving AI applications or models in the past two years. 27% of organizations report costs exceeding $1 million from AI-related security incidents.As organizational cyber maturity increases, the likelihood of experiencing an incident involving AI reduces significantly, from 89% (very low maturity) to 54% (very high maturity).
NEW YORK, April 21, 2026 /PRNewswire/ — Kroll, the leading independent provider of global financial and risk advisory solutions, has released global cyber resilience research which reveals that rapid artificial intelligence (AI) adoption is dramatically outpacing governance, security controls and incident preparedness.
It has become clear that AI, and in particular agentic AI, has changed the threat model permanently. The research results indicate that while AI is becoming embedded across enterprise operations, 76% of businesses have experienced a security incident involving AI applications or models in the past two years. The research reveals organizations lack the foundational security practices and governance frameworks necessary to deploy AI safely and effectively, costing almost one-third of organizations (27%) over one million dollars related to AI-related security incidents.
While there is appetite to incorporate the promise of AI into security infrastructure, 90% of respondents surveyed identified barriers preventing greater investment in AI security. Lack of clear ROI, insufficient executive understanding of AI risks and the belief that current measures are sufficient account for 40% of those barriers.
The Innovation-Security Trade-Off
The research shows that most organizations are inadequately prepared for AI threats, despite the rapid increase in attacks.
Organizations spend an average of 13% of their AI initiative budget on using AI to test security controls or to test the models themselves, leaving critical gaps in AI security posture and illuminating a disconnect between AI adoption and AI security investment.Companies with highly mature security practices are six times more likely to spend over 20% of their AI budget on testing security controls.Almost half (48%) of respondents stated they have little to no organizational governance on AI tool and service adoption, creating an expanded attack surface that extends far beyond the organization’s traditional perimeter.
Dave Burg, Global Group Head of Cyber and Data Resilience at Kroll, says, “Organizations are under pressure to embrace AI to respond faster and with greater precision to increasingly complex threats. However, this cannot come at the expense of the basics for prevention, detection and responding to attacks. We’re seeing businesses enthusiastically integrate AI into their operations without getting the fundamentals right first, and that’s creating a dangerous security debt.
The real story isn’t that AI is risky; it’s that without the right foundational security in place, AI amplifies existing security weaknesses. Fortunately, there are opportunities for organizations to remediate this. Kroll was recently among industry leaders joining CrowdStrike’s Charlotte AI AgentWorks Ecosystem which helps operationalize AI within managed detection and response, building tailored agents that accelerate investigations and response.”
Maturity Matters: Organizations with Strong Foundations Experience Significantly Fewer AI Incidents
As organizational cyber maturity increases, the likelihood of experiencing an AI-related security incident drops significantly:
89% of organizations with very low cyber maturity experience AI-related security incidents.In contrast, 54% of organizations with very high cyber maturity experience AI-related security incidents.Even further, 46% of organizations with very high cyber maturity reported zero AI-related cyber incidents in the past two years, demonstrating that robust security foundations directly translate to AI security resilience.This is understandable as 69% of organizations with very high cyber maturity have a centralized AI platform strategy with security controls, compared to just 39% of those with very low cyber maturity.
Quiessence Philips, Head of Security Architecture and Engineering at Kroll, says, “AI’s ability to accelerate productivity and innovation is undeniable, and the goal is not to slow it down. However, adoption without concurrent investment in security foundations is not bold, it’s reckless. The agentic AI ecosystem is now the fastest-growing enterprise attack surface, and the organizations most at risk are the ones chasing the opportunity without building security alongside it. Secure architecture, identity management, incident response, security culture – these aren’t limitations on innovation, but what make innovation sustainable.”
You can access the full report on the Kroll website.
You can also register for the webinar discussing these results in-depth here.
About the Research
Kroll commissioned independent research firm Sapio Research to conduct a comprehensive study into cybersecurity resilience and risk alignment in enterprise organizations. The research surveyed 1,000 cybersecurity decision-makers at companies with annual revenues from $50 million to more than $5 billion across 10 countries: the United Kingdom, Ireland, Germany, Switzerland, the United States, Japan, Singapore, Australia, the United Arab Emirates and Saudi Arabia. The survey was conducted in November and December 2025.
About Kroll
As the leading independent provider of financial and risk advisory solutions, Kroll leverages our unique insights, data and technology to help clients stay ahead of complex valuation demands. Kroll’s team of more than 6,500 professionals worldwide continues the firm’s nearly 100-year history of trusted expertise spanning risk, governance, transactions and valuation. Our advanced solutions and intelligence provide clients the foresight they need to create an enduring competitive advantage. At Kroll, our values define who we are and how we partner with clients and communities. Learn more at kroll.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-innovation-surges-as-security-fundamentals-lag-kroll-research-finds-302747672.html
SOURCE Kroll
LONDON, April 21, 2026 /PRNewswire/ — Premialab, the leading independent platform for quantitative analytics and systematic investment strategies, today announced that BBVA Global Markets QIS has joined its global contributor network. BBVA GM QIS will add its suite of rule-based strategies to the Premialab platform and leverage Premialab’s advanced analytics, including its Pure Factors framework, to independently benchmark and analyze performance and risk characteristics. This collaboration underscores Premialab’s commitment to deepening its quantitative solutions ecosystem and offering institutional investors a broader toolkit of data-driven strategies.
BBVA GM QIS offers a diverse suite of systematic strategies spanning equities including thematic and smart beta and systematic asset allocation, both aligned with its well-established Structured Products platform, as well as Alternative Risk Premia indices designed to capture systematic risk premiums available in the market. These solutions can also serve as overlays to traditional portfolios, providing additional income or hedging features.
Together, these investable systematic strategies enable investors to achieve their risk-return objectives by calibrating factor exposures and risk budgets in a flexible, transparent, and cost-efficient manner.
“Joining the Premialab platform is an exciting step for BBVA GM QIS,” said Pablo Suárez, Head of QIS at BBVA Global Markets. “We see Premialab as a natural partner, given the strong alignment between its independent analytics capabilities and our systematic investment framework. Its data infrastructure provides an ideal environment to showcase our strategies to a global institutional audience. This collaboration reflects our commitment to working closely together, enabling investors to better understand the risk and return drivers of our systematic solutions and how they can complement their broader portfolio objectives.”
We are delighted to partner with BBVA GM QIS,” said Adrien Geliot, CEO of Premialab. “Their quantitative expertise and strong track record in developing innovative, rule-based investment solutions align with our mission to bring greater transparency, consistency, and insight to the systematic investing landscape. This partnership expands our coverage and strengthens the value we deliver to institutional investors.
Premialab’s multi-asset, multi-region platform handles over 15 million data points daily across more than 7,000 investible systematic strategies, representing client assets under management of approximately USD 20 trillion. Its proprietary dataset and analytics provide detailed risk decomposition, factor attribution, and scenario-based analysis – enabling investors to make better allocation decisions.
Notes to Editors
About Premialab
Premialab is the leading independent platform that collaborates with leading investment banks and institutional investors globally, providing data, analytics, and risk solutions for systematic, factor, and multi-asset strategies. With offices in London, Paris, New York, Hong Kong, Dubai and Sydney, the company partners with the top 18 investment banks, leading asset managers, pension funds, sovereign wealth funds and insurance companies globally. For more information, please visit: www.premialab.com.
About BBVA CIB
BBVA is a global financial services group founded in 1857. The bank is present in more than 25 countries, has a strong leadership position in the Spanish market, is the largest financial institution in Mexico and it has leading franchises in South America and Turkey. In the United States, BBVA also has a significant investment, transactional, and capital markets banking business.
Its division BBVA Corporate & Investment Banking (BBVA CIB) brings together the activities of investment banking, markets, financing and transactional services for institutional investors and corporate clients. It has a strong global presence, providing services in 25 countries through an extensive team of experts, including investment banking specialists and advisors in specific industries and sectors. BBVA CIB offers a wide range of value-added products and financial solutions, for the simplest needs and for the most complex ones. Its mission is to help clients to carry out their projects and achieve their business, transformation and sustainability objectives, whether they are local or international.
Logo: https://mma.prnewswire.com/media/2752715/5584590/Premialab_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/premialab-partners-with-bbva-cib-302747587.html
Wearable Technology Market Expected to Reach $183.2 Billion by 2031, Growing at a CAGR of 12.75% — Allied Market Research
AI Innovation Surges as Security Fundamentals Lag, Kroll Research Finds
Premialab Partners with BBVA CIB
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Send Rakhi to UK swiftly with UK Gifts Portal
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoInterfaith America Works to Promote Free, Fair and Peaceful Elections
-
Coin Market4 days agoFrench finance minister backs euro-pegged stablecoins to compete with US
-
Technology2 days agoHarmonic Enables DIRECTV to Reimagine Nationwide DTH Service
-
Near Videos4 days agoWe Have Only Scratched The Surface Of The Agentic Future
-
Coin Market4 days agoSingapore Gulf Bank adds stablecoin mint and redeem for 24/7 settlement
-
Near Videos4 days agoAnthropic Cuts Off OpenClaw Subscribers | GPT-Image-2 Leaked | Drift $285M Hack Explained
-
Near Videos4 days agoNEAR Intern Demos the Future of Private Trading
-
Technology4 days agoDynamite Integrates Biometric Cryptography and AI into its Wallet Product
